Hercules Capital Provides $75MM Credit Facility to Viridian Therapeutics

Viridian Therapeutics, a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, entered into a debt financing agreement with Hercules Capital for up to $75 million.

April 5, 2022 Cristy Barnes | Hercules Capital | Kristian Humer | Viridian Therapeutics Ian Koplin

Hercules Capital Expands TG Therapeutics’ Term Loan to $200MM

Hercules Capital amended TG Therapeutics’ existing term loan facility agreement to increase the size of the facility to $200 million, with $70 million funded at closing.

January 5, 2022 Hercules Capital | Michael Dutra | Michael S. Weiss | TG Therapeutics Ian Koplin

Hercules Capital Surpasses $2B in Annual Gross Debt and Equity Commitments

Hercules Capital has originated more than $2 billion year to date in annual total gross debt and equity commitments, breaking its previous one-year record of $1.47 billion.

November 29, 2021 Hercules Capital | Scott Bluestein Ian Koplin

SMBC Provides $100MM Multi-Currency Credit Facility to Hercules Capital

Hercules Capital, a specialty financing provider to companies backed by venture capital and select private equity firms, entered into a $100 million multi-currency credit facility with Sumitomo Mitsui Banking Corporation.

November 11, 2021 Hercules Capital | Seth Meyer | Sumitomo Mitsui Banking Corporation Ian Koplin

Hercules Capital Provides $25MM Credit Facility to Locus Biosciences

Locus Biosciences, a clinical-stage biotechnology company developing a new class of precision engineered bacteriophage treatments for bacterial and inflammatory diseases, entered a credit facility of up to $25 million with Hercules Capital.

October 20, 2021 Bryan Jadot | Hercules Capital | Locus Biosciences | Paul Garofolo Ian Koplin

Hercules Capital Expands Term Loan Facility to $300MM for Axsome Therapeutics

Hercules Capital amended the existing term loan facility agreement it has with Axsome Therapeutics to increase the size of the facility to $300 million and the amount immediately available upon FDA approval of AXS-05 for major depressive disorder to $100 million at the company’s option.

October 19, 2021 Axsome Therapeutics | Hercules Capital | Herriot Tabuteau | Michael Dutra Ian Koplin

Hercules Capital Provides $30MM Debt Facility to Eloxx Pharmaceuticals

Eloxx Pharmaceuticals entered into a debt facility of up to $30 million with Hercules Capital, a specialty financing lender for life science and technology companies. Eloxx has drawn the initial tranche of $12.5 million and used the proceeds to repay in full amounts outstanding under its existing debt facility.

October 6, 2021 Eloxx Pharmaceuticals | Hercules Capital | Janice Bourque | Sumit Aggarwal Ian Koplin

Hercules Capital Provides $235MM to Corium, Surpasses $1.5B in Commitments in 2021

Corium, a commercial-stage biopharmaceutical company, closed on a $235 million term loan agreement with Hercules Capital. Hercules Capital also reported it has originated more than $1.5 billion year to date in annual total gross debt and equity commitments in 2021, breaking its previous one-year record.

September 28, 2021 Corium | Hercules Capital | J. Wood Capital Advisors | Michael Dutra | Perry J. Sternberg | Scott Bluestein Ian Koplin

Hercules Capital Provides $200MM Term Loan to Phantom Pharmaceuticals

Phathom Pharmaceuticals, a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, obtained a $200 million term loan facility from Hercules Capital.

September 21, 2021 Armentum Partners | Bryan Jadot | Hercules Capital | Lake McGuire | Phathom Pharmaceuticals | Terrie Curran Ian Koplin

Hercules Capital Provides $50MM Debt Facility to Better Therapeutics

Better Therapeutics, a prescription digital therapeutics company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases, secured a loan facility for up to $50 million from Hercules Capital.

August 26, 2021 Better Therapeutics | Cristy Barnes | Hercules Capital | Kevin Appelbaum | Mark Heinen Ian Koplin